Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results-Reference-Cited by-同舟云学术

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Published:2015-02-26 Issue:9 Volume:125 Page:1411-1417
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Leleu Xavier¹,Karlin Lionel²,Macro Margaret³,Hulin Cyrille⁴,Garderet Laurent⁵,Roussel Murielle⁶,Arnulf Bertrand⁷,Pegourie Brigitte⁸,Kolb Brigitte⁹,Stoppa Anne Marie¹⁰,Brechiniac Sabine¹¹,Marit Gerald¹²,Thielemans Beatrice¹,Onraed Brigitte¹,Mathiot Claire¹³,Banos Anne¹⁴,Lacotte Laurence¹⁵,Tiab Mourad¹⁶,Dib Mamoun¹⁷,Fuzibet Jean-Gabriel¹⁸,Petillon Marie Odile¹,Rodon Philippe¹⁹,Wetterwald Marc²⁰,Royer Bruno²¹,Legros Laurence¹⁸,Benboubker Lotfi²²,Decaux Olivier²³,Escoffre-Barbe Martine²⁴,Caillot Denis²⁵,Fermand Jean Paul⁷,Moreau Philippe²⁶,Attal Michel⁶,Avet-Loiseau Herve⁶,Facon Thierry¹

Affiliation:

1. Hôpital Huriez, Lille, France;

2. Hôpital Lyon Sud, Lyon Pierre Benite, France;

3. Hôpital Côte de Nacre, Caen, France;

4. Hôpital de Brabois, Nancy Vandoeuvre, France;

5. Hôpital Saint Antoine, Assistance Publiques des Hôpitaux de Paris, Paris, France;

6. Hôpital Purpan, Toulouse, France;

7. Hôpital Saint Louis, Assistance Publique–Hôpitaux de Paris, Paris, France;

8. Hôpital A. Michallon, Grenoble, France;

9. Hôpital Robert Debré, Reims, France;

10. Institut Paoli Calmettes, Marseille, France;

11. Hôpital Bobigny-Avicennes, Assistance Publiques–Hôpitaux de Paris, Paris, France;

12. Hôpital du Haut-Lévèque, Bordeaux Pessac, France;

13. Institut Curie, Paris, France;

14. Hôpital de la côte basque, Bayonne, France;

15. Hôpital Jean Bernard, Poitiers, France;

16. Hôpital Départemental, La Roche sur Yon, France;

17. Hôpital du Bocage, Angers, France;

18. Hôpital Archet, Nice, France;

19. Hopital de Perigueux, Perigueux, France;

20. Hôpital Général, Dunkerque, France;

21. Hôpital Sud, Amiens, France;

22. Hôpital Bretonneau, Tours, France;

23. Hôpital Sud, Rennes, France;

24. Hôpital Pontchaillou, Rennes, France;

25. Hôpital d’Enfants, Dijon, France; and

26. Hotel Dieu, Nantes, France

Abstract

Key Points Pom-Dex is active and well tolerated in adverse cytogenetic patients with early RRMM, particularly in those with del(17p). Pom-Dex prolonged OS in adverse cytogenetic patients with early RRMM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/9/1411/1388370/1411.pdf

Reference28 articles.

1. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.;Dewald;Blood,2005

2. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.;Avet-Loiseau;Blood,2007

3. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.;Gertz;Blood,2005

4. Review of molecular diagnostics in multiple myeloma.;Stewart;Expert Rev Mol Diagn,2007

5. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.;Fonseca;Blood,2003

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenic therapy: new actors in myeloma;Blood;2024-06-20

2. Помалидомид в терапии рецидивирующей/рефрактерной множественной миеломы;Journal of Modern Oncology;2023-08-10

3. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma;British Journal of Haematology;2023-03-27

4. Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review;International Journal of Hematology;2023-02-03

5. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice;International Journal of Hematology;2023-01-24